Ownership and insider activity for Damora Therapeutics, Inc. (GLTO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Price
| Price | $21.58 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-02-09 | Bruno Julianne | M-Exempt | 129,000 | |
| 2026-02-09 | Bruno Julianne | M-Exempt | 129 | |
| 2026-02-09 | Fairmount Funds Management LLC | M-Exempt | 5,809,000 | |
| 2026-02-09 | Fairmount Funds Management LLC | M-Exempt | 2,904,000 | |
| 2026-02-09 | Fairmount Funds Management LLC | M-Exempt | 5,809 | |
| 2026-02-09 | Fairmount Funds Management LLC | M-Exempt | 2,904 | |
| 2026-01-05 | Sattarzadeh Sherwin | A-Award | 444,209 | $9.7M |
| 2026-01-05 | Sattarzadeh Sherwin | A-Award | 190,376 | |
| 2026-01-05 | Sattarzadeh Sherwin | |||
| 2026-01-05 | Hewes L. Becker | A-Award | 528,603 | $11.5M |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.0M | $11.3M | $163.6M | $62.6M | $32.8M | $21.5M | $14.2M | $257.6M |
| Short-term Investments | 0 | 0 | 0 | $37.6M | $27.4M | $11.7M | 0 | 0 |
| Receivables | $989000 | $41.1M | $2.2M | $2.3M | $1.4M | $1.7M | $881000 | $899000 |
| Inventory | $3.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $35.0M | $56.1M | $169.3M | $110.1M | $63.9M | $36.8M | $16.8M | $260.4M |
| Property, Plant & Equipment | 0 | $298000 | $885000 | $1.0M | $1.2M | $325000 | $130000 | $104000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $35.1M | $56.6M | $171.6M | $122.2M | $73.2M | $38.2M | $17.1M | $260.5M |
| Accounts Payable | $1.4M | $3.3M | $2.9M | $1.5M | $3.4M | $1.7M | $377000 | $444000 |
| Short-term Debt | 0 | $87000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.4M | $7.9M | $5.6M | $4.5M | $11.1M | $5.8M | $1.2M | $20.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $4.4M | $8.1M | $6.1M | $5.0M | $11.4M | $5.9M | $1.3M | $20.1M |
| Retained Earnings | -$33.0M | -$69.5M | -$104.4M | -$156.1M | -$217.7M | -$256.1M | -$277.5M | -$487.4M |
| Total Equity | $30.7M | $48.5M | $165.5M | $117.2M | $61.8M | $32.3M | $15.8M | $240.4M |
| Total Debt | 0 | $298000 | $915000 | $847000 | $804000 | $249000 | $73000 | $68000 |
| Net Debt | -$31.0M | -$11.0M | -$162.7M | -$99.3M | -$59.4M | -$32.9M | -$14.1M | -$257.6M |
| Working Capital | $30.5M | $48.2M | $163.7M | $105.6M | $52.8M | $30.9M | $15.6M | $240.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 19.73 |
Profitability
| Return on Equity | -82.56% |
| Return on Invested Capital | -52.44% |
| Return on Assets | -48.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · INAB · KPRX
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of GLTO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks